Table 1.
Characteristics of included studies
| Study characteristics | n | % |
|---|---|---|
| Province | ||
| Ontario | 8 | 32 |
| British Columbia | 8 | 32 |
| Prairies (Alberta and Manitoba) | 4 | 16 |
| Canada-Wide | 2 | 8 |
| Quebec (alone or with USA) | 2 | 8 |
| Maritimes (Nova Scotia) | 1 | 4 |
| Study funding | ||
| Public | 19 | 76 |
| Not stated | 3 | 12 |
| Private | 1 | 4 |
| Public and private | 1 | 4 |
| None | 1 | 4 |
| Year of publication | ||
| 2016–2018 | 12 | 48 |
| 2013–2015 | 9 | 36 |
| 2010–2012 | 4 | 16 |
| Clinical context | ||
| Oncology | 15 | 60 |
| Rare diseases | 5 | 20 |
| Multiple/not specific | 3 | 12 |
| Prenatal screening | 2 | 8 |
| NGS technology | ||
| NGS panels | 13 | 52 |
| Oncotype DX | 6 | 24 |
| WGS/WGTA | 5 | 20 |
| Not specific | 4 | 16 |
| WES and WGS | 2 | 8 |
| WES | 1 | 4 |
| Test strategy | ||
| Prognosis | 10 | 40 |
| Diagnosis | 9 | 36 |
| Guide treatment | 3 | 12 |
| Other/multiple | 3 | 12 |
WES, whole-exome sequencing; WGS/WGTA, whole-genome sequencing/whole-genome and transcriptome analysis, including cell-free DNA testing